Project Grant 1938096

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...

Hermes Life Sciences LTD received a $1,126,590 cooperative agreement award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to support the SBIR PHASE II: BLOOD-PLASMA SEPARATION FOR POINT-OF-CARE DIAGNOSTIC TESTING project. The funding period is from August 1, 2021 through January 31, 2024. Under this cooperative agreement, Hermes Life Sciences LTD will develop technologies for blood-plasma separation to enable point-of-care...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop a novel SPINEX (Separation-Processing Integration for Extracellular Vesicles) platform to streamline sample preparation for isolating extracellular vesicles (EVs) from clinical plasma samples. The $231,413 award to The General Hospital Corporation (Massachusetts General Hospital) will fund the implementation of a fully automated, multi-functional SPINEX system...

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $1,077,369 to Captis Diagnostics Inc., a small disadvantaged business, to develop and commercialize a proprietary Lipid Nanoprobe (LNP) system for rapid and efficient isolation of extracellular vesicles (EVs) from bodily fluids such as blood, urine, and saliva. The goal is to enable comprehensive multi-omics (genomics, epigenetics, transcriptomics, proteomics) molecular...

This Small Business Innovation Research (SBIR) Phase II Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $1,250,000 to Prompt Diagnostics, Inc. to develop an automated, point-of-care diagnostic device for infections caused by Treponema pallidum. The device is designed to accelerate pathogen detection and reduce the interval between testing and treatment, which may help lower rates of perinatal...

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $487,350 Project Grant (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health) to Trustees of Tufts College (Tufts University) to develop paper-based microsampling devices for collecting and stabilizing dried blood and plasma samples. The goal is to enable patient-centric, at-home blood collection and sample transport that can be integrated into existing clinical...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care test for measuring anti-Factor Xa activity and hemoglobin levels. This diagnostic tool aims to guide emergency management of patients on direct oral anticoagulants, enabling faster delivery of life-saving interventions such as andexanet alfa for bleeding or thrombolytics for acute ischemic...

This $249,000 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of a novel split enzyme diagnostic platform for rapid, sensitive detection of protein and small molecule biomarkers at the point of care. The key products and services to be delivered through this grant include: Incorporating binding domains...

This $255,706 National Science Foundation SBIR Phase I Project Grant to Metfora LLC supports the development of a novel multiplexed metabolite diagnostic blood test for early detection of chronic diseases. The NSF Technology, Innovation, and Partnerships program aims to advance science and engineering solutions to national challenges through innovation and partnerships. Specifically, Metfora will use mass spectrometry and artificial intelligence to analyze specific panels of circulating...